Posted by Michael Wonder on 01 Jun 2022
Cancer, rare disorder advocates call for more radical change after damning PHARMAC review
2 June 2022 - Radical action is needed urgently to tackle the delays patients face in getting the latest drugs for a raft of diseases and conditions, health advocates say, after a review into the medicine-buying agency found “deficiencies” in its decision-making.
“PHARMAC is based on cost saving,” Ah-Leen Rayner, chief executive of the Breast Cancer Foundation said. “Whilst back in the day it may have delivered to its purpose, I think that methodology has to now change.”
